ECSP088986A - Formulaciones galénicas de alisquireno e hidroclorotiazida - Google Patents

Formulaciones galénicas de alisquireno e hidroclorotiazida

Info

Publication number
ECSP088986A
ECSP088986A EC2008008986A ECSP088986A ECSP088986A EC SP088986 A ECSP088986 A EC SP088986A EC 2008008986 A EC2008008986 A EC 2008008986A EC SP088986 A ECSP088986 A EC SP088986A EC SP088986 A ECSP088986 A EC SP088986A
Authority
EC
Ecuador
Prior art keywords
hydroclorotiazida
alisquireno
galenic formulations
combinations
effective amount
Prior art date
Application number
EC2008008986A
Other languages
English (en)
Spanish (es)
Inventor
Matthias Willmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088986A publication Critical patent/ECSP088986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EC2008008986A 2006-06-23 2008-12-17 Formulaciones galénicas de alisquireno e hidroclorotiazida ECSP088986A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
ECSP088986A true ECSP088986A (es) 2009-01-30

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008986A ECSP088986A (es) 2006-06-23 2008-12-17 Formulaciones galénicas de alisquireno e hidroclorotiazida

Country Status (26)

Country Link
US (1) US8618172B2 (enExample)
EP (3) EP2034968B1 (enExample)
JP (1) JP5362556B2 (enExample)
KR (1) KR101442272B1 (enExample)
CN (1) CN101472566A (enExample)
AR (1) AR061565A1 (enExample)
AU (1) AU2007263261B2 (enExample)
BR (1) BRPI0713338A2 (enExample)
CA (1) CA2654872A1 (enExample)
CL (1) CL2007001837A1 (enExample)
EC (1) ECSP088986A (enExample)
ES (1) ES2704979T3 (enExample)
GB (1) GB0612540D0 (enExample)
GT (1) GT200800297A (enExample)
IL (1) IL195425A (enExample)
MA (1) MA30527B1 (enExample)
MX (1) MX2008016533A (enExample)
MY (1) MY146779A (enExample)
NO (1) NO20090262L (enExample)
NZ (1) NZ572937A (enExample)
PE (2) PE20120990A1 (enExample)
RU (1) RU2491058C2 (enExample)
TN (1) TNSN08528A1 (enExample)
TW (1) TWI457137B (enExample)
WO (1) WO2007147596A1 (enExample)
ZA (1) ZA200809773B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2483718C2 (ru) * 2007-09-28 2013-06-10 Новартис Аг Галеновые композиции алискирена
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
US9301918B2 (en) * 2013-03-15 2016-04-05 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
AU2003240669B2 (en) * 2002-05-17 2007-03-08 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
KR20080000624A (ko) 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법
EP1940374A2 (en) * 2005-10-21 2008-07-09 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Also Published As

Publication number Publication date
EP2034968B1 (en) 2018-10-31
US8618172B2 (en) 2013-12-31
JP2009541239A (ja) 2009-11-26
BRPI0713338A2 (pt) 2012-03-06
NZ572937A (en) 2011-11-25
CN101472566A (zh) 2009-07-01
AR061565A1 (es) 2008-09-03
IL195425A (en) 2014-01-30
AU2007263261B2 (en) 2011-07-14
TW200808358A (en) 2008-02-16
EP2311439A1 (en) 2011-04-20
ES2704979T3 (es) 2019-03-21
CA2654872A1 (en) 2007-12-27
EP3391878A1 (en) 2018-10-24
GB0612540D0 (en) 2006-08-02
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
US20090203679A1 (en) 2009-08-13
KR20090021353A (ko) 2009-03-03
RU2491058C2 (ru) 2013-08-27
EP2034968A1 (en) 2009-03-18
KR101442272B1 (ko) 2014-09-22
WO2007147596A1 (en) 2007-12-27
PE20080373A1 (es) 2008-06-06
PE20120990A1 (es) 2012-08-16
TWI457137B (zh) 2014-10-21
GT200800297A (es) 2009-03-09
IL195425A0 (en) 2009-08-03
TNSN08528A1 (en) 2010-04-14
MY146779A (en) 2012-09-28
RU2009101971A (ru) 2010-07-27
CL2007001837A1 (es) 2008-06-13
JP5362556B2 (ja) 2013-12-11
ZA200809773B (en) 2009-11-25
AU2007263261A1 (en) 2007-12-27
NO20090262L (no) 2009-01-19

Similar Documents

Publication Publication Date Title
ECSP088986A (es) Formulaciones galénicas de alisquireno e hidroclorotiazida
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
ECSP088980A (es) Composicion farmacéutica que comprende amlodipina y losartán
CO6361904A2 (es) Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo
DOP2006000170A (es) Nuevos derivados de espirocromanona
CU20080235A7 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
WO2009088414A3 (en) Oral pharmaceutical dosage forms
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
PE20110435A1 (es) Composiciones antagonistas del pd-1
CO6400185A2 (es) Formas de dosificación sólida de bendamustina
AR053809A1 (es) Combinacion de compuestos organicos
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
UA110207C2 (xx) ФАРМАЦЕВТИЧНА ТАБЛЕТКА, ЯКА МІСТИТЬ 1-(β-D-ГЛЮКОПІРАНОЗИЛ)-4-МЕТИЛ-3-$5-(4-ФТОРФЕНІЛ)-2-ТІЄНІЛМЕТИЛ]БЕНЗОЛ ЯК ІНГІБІТОР НАТРІЙЗАЛЕЖНОГО ПЕРЕНОСНИКА ГЛЮКОЗИ (НЗПГ)
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
WO2011023367A3 (en) Bisphosphonate-prodrugs
EP2420231A3 (en) Angiotensin II receptor antagonist for the prevention or treatment of cardiovascular disease in cats
EP2062579A4 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING OPTICALLY STABLE RAMOSETRON
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
WO2010029093A3 (en) Compositions for percutaneous administration
DE602007007968D1 (de) Pharmazeutische Formulierungen mit Irbesartan